Novartis Stalevo approval in Parkinson’s
Executive Summary
FDA approves Orion/Novartis' Stalevo June 12 for treatment of idiopathic Parkinson's disease. One of Stalevo's indications in labeling is as substitute "for immediate release carbidopa/levodopa and entacapone (Orion/Novartis' Comtan) previously administered as individual products." Stalevo is combination of carbidopa (12.5 mg, 25 mg or 37.5 mg), levodopa (50 mg, 100 mg or 150 mg) and entacapone (200 mg). Labeling suggests easy switch from Comtan 200 mg to the corresponding strength of Stalevo with same amounts of levodopa and carbidopa...
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.